[Treatment of acute destructive pancreatitis with recombinant interleukin-2].
Twenty-nine patients with acute destructive pancreatitis received combined therapy including recombinant interleukin-2 (ronkoleukin). Treatment with this interleukin led to a decrease of hypercytokinemia, reduced rate of purulent -- septic complications and surgical operations because of these complications.
Sotnichenko
B A
BA
Markelova
E V
EV
Salienko
S V
SV
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007371:Interferon-gamma / Q000097:blood; D007376:Interleukin-2 / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D015847:Interleukin-4 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008297:Male; D008875:Middle Aged; D019283:Pancreatitis, Acute Necrotizing / Q000097:blood / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000970:Antineoplastic Agents; D015415:Biomarkers; D007376:Interleukin-2; D016209:Interleukin-8; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D007371:Interferon-gamma